Antimicrobials: access and sustainable eff ectiveness 1 Access to eff ective antimicrobials: a worldwide challenge

By Ramanan Laxminarayan, P. Matsoso, Suraj Pant, C. Brower, J. Røttingen, K. Klugman, SallyC. Davies. 2015

1,013 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Infectious Disease Threats in the Twenty-First Century: Strengthening the Global Response (2019, background): “The baked-in nature of the problem is compounded by the fact that there is currently tremendous need for increased access to antimicrobials in low-and middle-income countries (LMICs), where many continue to die every year from infectious diseases that are easily treated in the developed world (77) .”
Antimicrobial photodynamic therapy – what we know and what we don’t (2018, background): “aureus (MRSA) strains and the multi-resistant extended spectrum beta-lactamase (ESBL)-producing bacteria have become established pathogens in hospitals (McCarthy et al. 2010; Holmes et al. 2016; Laxminarayan et al. 2016).”
Global increase and geographic convergence in antibiotic consumption between 2000 and 2015 (2018, background): “This is further compounded by rising resistance to affordable first-line treatments, which already prevents the most vulnerable populations from accessing effective treatments in some countries (1).”
Prioritization of pathogens to guide discovery, research and development of new antibiotics for drug resistant bacterial infections, including tuberculosis (2017, background): “China, Democratic Republic of the Congo, India, Nigeria, Pakistan (44)”